244 related articles for article (PubMed ID: 19846535)
1. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
[TBL] [Abstract][Full Text] [Related]
2. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
[TBL] [Abstract][Full Text] [Related]
3. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.
Nozawa Y; Umemura T; Joshita S; Katsuyama Y; Shibata S; Kimura T; Morita S; Komatsu M; Matsumoto A; Tanaka E; Ota M
PLoS One; 2013; 8(12):e83381. PubMed ID: 24349500
[TBL] [Abstract][Full Text] [Related]
4. Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
Vidal-Castiñeira JR; López-Vázquez A; Martínez-Borra J; Martínez-Camblor P; Prieto J; López-Rodríguez R; Sanz-Cameno P; de la Vega J; Rodrigo L; Pérez-López R; Pérez-Álvarez R; López-Larrea C
PLoS One; 2014; 9(6):e99426. PubMed ID: 24927414
[TBL] [Abstract][Full Text] [Related]
5. Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
Askar M; Avery R; Corey R; Lopez R; Thomas D; Pidwell D; Eghtesad B; Miller C; Fung J; Zein NN
Liver Transpl; 2009 Nov; 15(11):1557-63. PubMed ID: 19877200
[TBL] [Abstract][Full Text] [Related]
6. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population.
Shan Z; Huang J; Liao Q; Huang K; Wang M; Xu R; Tang X; Zhang W; Nelson K; Fu Y; Li C; Rong X
Transfusion; 2018 Apr; 58(4):1028-1035. PubMed ID: 29446443
[TBL] [Abstract][Full Text] [Related]
7. Killer cell immunoglobulin-like receptors and response to antiviral treatment in Thai patients with chronic hepatitis C virus genotype 3a.
Vejbaesya S; Nonnoi Y; Tanwandee T; Srinak D
J Med Virol; 2011 Oct; 83(10):1733-7. PubMed ID: 21755501
[TBL] [Abstract][Full Text] [Related]
8. Protective KIR-HLA interactions for HCV infection in intravenous drug users.
Zúñiga J; Romero V; Azocar J; Terreros D; Vargas-Rojas MI; Torres-García D; Jiménez-Alvarez L; Vargas-Alarcón G; Granados-Montiel J; Husain Z; Chung RT; Alper CA; Yunis EJ
Mol Immunol; 2009 Aug; 46(13):2723-7. PubMed ID: 19552960
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histopathological changes in different KIR gene profiles in chronic HCV Romanian patients.
Ursu LD; Calenic B; Diculescu M; Dima A; Stoian IT; Constantinescu I
Int J Immunogenet; 2021 Feb; 48(1):16-24. PubMed ID: 32961633
[TBL] [Abstract][Full Text] [Related]
10. Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals.
Legrand N; David G; Rodallec A; Gaultier A; Salmon D; Cesbron A; Wittkop L; Raffi F; Gendzekhadze K; Retière C; Allavena C; Gagne K
Clin Exp Immunol; 2021 Apr; 204(1):107-124. PubMed ID: 33314121
[TBL] [Abstract][Full Text] [Related]
11. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
12. Contribution of genes for killer cell immunoglobulin-like receptors (KIR) to the susceptibility to chronic hepatitis C virus infection and to viremia.
Kuśnierczyk P; Mozer-Lisewska I; Zwolińska K; Kowala-Piaskowska AE; Bura M; Bereszyńska I; Pauli A; Żeromski J
Hum Immunol; 2015 Mar; 76(2-3):102-8. PubMed ID: 25636579
[TBL] [Abstract][Full Text] [Related]
13. HLA-C and KIR genes in hepatitis C virus infection.
Montes-Cano MA; Caro-Oleas JL; Romero-Gómez M; Diago M; Andrade R; Carmona I; Aguilar Reina J; Núñez-Roldán A; González-Escribano MF
Hum Immunol; 2005 Nov; 66(11):1106-9. PubMed ID: 16571411
[TBL] [Abstract][Full Text] [Related]
14. Association of NKG2A with treatment for chronic hepatitis C virus infection.
Harrison RJ; Ettorre A; Little AM; Khakoo SI
Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
[TBL] [Abstract][Full Text] [Related]
15. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
[TBL] [Abstract][Full Text] [Related]
16. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
17. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
[TBL] [Abstract][Full Text] [Related]
18. HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma.
Cariani E; Pilli M; Zerbini A; Rota C; Olivani A; Zanelli P; Zanetti A; Trenti T; Ferrari C; Missale G
Clin Cancer Res; 2013 Oct; 19(19):5465-73. PubMed ID: 23938290
[TBL] [Abstract][Full Text] [Related]
19. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population.
Auer ED; Tong HV; Amorim LM; Malheiros D; Hoan NX; Issler HC; Petzl-Erler ML; Beltrame MH; Boldt ABW; Toan NL; Song LH; Velavan TP; Augusto DG
Int J Infect Dis; 2020 Jul; 96():541-547. PubMed ID: 32422377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
